# A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)

> **NCT02627274** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 134 (actual)

## Conditions studied

- Solid Tumor
- Breast Cancer
- Cancer of Head and Neck

## Interventions

- **DRUG:** RO6874281
- **DRUG:** Trastuzumab
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT02627274
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-07
- **Primary completion:** 2022-11-10
- **Final completion:** 2022-11-10
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2022-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02627274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02627274, "A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT02627274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*